Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01790152 · ClinicalTrials.gov registry record

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

A clinical trial of Osteosarcoma and Lymphoblastic Lymphoma, sponsored by Children's Oncology Group.

Recruiting
Registry status
420
Enrollment target
20
Study locations

NCT01790152 is a study of Osteosarcoma and Lymphoblastic Lymphoma that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 420 participants, above the 293-participant average among 46 other Osteosarcoma trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01790152, a study of Osteosarcoma and Lymphoblastic Lymphoma, is actively recruiting participants, sponsored by Children's Oncology Group.

RECRUITING
Registry status
420 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.

Interventions

  • OTHER Quality-of-Life Assessment
  • OTHER Laboratory Biomarker Analysis
  • OTHER Questionnaire Administration
  • OTHER Assessment of Therapy Complications

Study Locations (20)

Florida

  • Golisano Children's Hospital of Southwest Florida - Fort Myers
  • University of Florida Health Science Center - Gainesville - Gainesville
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital - Hollywood
  • Nemours Children's Clinic-Jacksonville - Jacksonville
  • Nemours Children's Hospital - Orlando
  • Johns Hopkins All Children's Hospital - St. Petersburg
  • Saint Joseph's Hospital/Children's Hospital-Tampa - Tampa
  • Saint Mary's Hospital - West Palm Beach

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • Valley Children's Hospital - Madera
  • Kaiser Permanente-Oakland - Oakland
  • Lucile Packard Children's Hospital Stanford University - Palo Alto
  • Rady Children's Hospital - San Diego - San Diego

Arizona

  • Phoenix Childrens Hospital - Phoenix
  • Banner University Medical Center - Tucson - Tucson

Alabama

  • Children's Hospital of Alabama - Birmingham

Arkansas

  • Arkansas Children's Hospital - Little Rock

Connecticut

  • Yale University - New Haven

Georgia

  • Children's Healthcare of Atlanta - Egleston - Atlanta

Hawaii

  • University of Hawaii Cancer Center - Honolulu

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2014-03-05
Est. Completion 2025-12-31

Sponsor

Children's Oncology Group

342 total trials

What the Registry Record Tells You About NCT01790152

The ClinicalTrials.gov registry entry for NCT01790152 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 293-participant average among 46 other Osteosarcoma trials with a reported enrollment target (43% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Osteosarcoma appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT01790152 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT01790152 about?

NCT01790152 is a clinical study titled "Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment". This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of d...

What is the current status of trial NCT01790152?

This trial is currently recruiting. The enrollment target is 420 participants. The study started on 2014-03-05. Estimated completion is 2025-12-31.

What conditions does trial NCT01790152 study?

This clinical trial studies the following conditions: Osteosarcoma, Lymphoblastic Lymphoma, Recurrent Malignant Neoplasm, Recurrent Lymphoma, Recurrent Leukemia.

What interventions are being tested in trial NCT01790152?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Assessment of Therapy Complications (OTHER).

Who is sponsoring clinical trial NCT01790152?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01790152 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteosarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.